United States Catheter-Related Bloodstream Infection (CRBSI) Drugs Market Projected to Reach US$ 1.0 Billion by 2034, Driven by Rising Hospital Acquired Infections and Advanced Antimicrobial Therapies

Leander, Texas and Tokyo, Japan - Jan.09.2026, As per DataM intelligence research report "The Catheter-Related Bloodstream Infection Drugs Market reached US$ 1.61 billion in 2024 and is expected to reach US$ 2.65 billion by 2034, growing at a CAGR of 5.13% during the forecast period 2025-2034." Rising hospital acquired infections, antibiotic resistance challenges, and innovations in antimicrobial therapies are fueling growth in CRBSI treatment options.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/catheter-related-bloodstream-infection-drugs-market?praneetha

☛ United States: Recent Industry Developments
✅ In December 2025, CorMedix Therapeutics announced positive interim results from real world evidence studies on DefenCath (taurolidine/heparin) catheter lock solution, demonstrating reduced CRBSI rates in hemodialysis patients using central venous catheters.

✅ In November 2025, Leading U.S. providers advanced adoption of next generation antimicrobial lock solutions and coated catheters, supporting infection prevention in high-risk oncology and ICU settings.

✅ In October 2025, Pfizer progressed novel antibiotic formulations targeting multi-drug resistant pathogens in CRBSI, enhancing treatment efficacy for catheter associated infections.

✅ In September 2025, Clinical advancements highlighted expanded use of taurolidine based therapies post FDA approval expansions, reducing recurrence in vulnerable patient populations.

☛ Japan: Recent Industry Developments
✅ In December 2025, Japanese hospitals increased integration of advanced antimicrobial agents and catheter lock solutions for CRBSI management, aligning with national infection control priorities.

✅ In November 2025, Collaborations focused on nanotechnology based antimicrobial coatings for catheters, improving prevention strategies in aging patient demographics.

✅ In October 2025, Takeda Pharmaceutical advanced targeted therapies for multi-drug resistant CRBSI, emphasizing safety and efficacy in hospitalized patients.

✅ In September 2025, Astellas Pharma expanded clinical evaluations of novel antimicrobials, supporting early intervention in catheter related infections.

☛ Catheter-Related Bloodstream Infection Drugs Market: Drivers
The Catheter-Related Bloodstream Infection (CRBSI) Drugs market is growing due to increasing catheter usage in chronic treatments like hemodialysis, chemotherapy, and ICU care, elevating infection risks. Rising antimicrobial resistance complicates standard treatments, driving demand for novel antibiotics, antifungals, and lock solutions. Advancements in preventive therapies, such as antimicrobial coated catheters and taurolidine/heparin solutions, reduce incidence and healthcare costs. Growing awareness of hospital-acquired infections, regulatory focus on prevention, and R&D investments in targeted therapies support expansion. Aging populations and higher chronic disease prevalence further accelerate need for effective CRBSI management.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/catheter-related-bloodstream-infection-drugs-market?praneetha

☛ Catheter-Related Bloodstream Infection Drugs Market: Major Players
Hikma Pharmaceuticals PLC, Pfizer Inc., Merck & Co., Inc., Baxter International Inc., Fresenius Kabi USA, CorMedix Inc., Citius Pharmaceuticals, Xellia Pharmaceuticals, SteriMax Inc., AdvaCare Pharma, and others.

☛ Segment Covered in the Catheter-Related Bloodstream Infection Drugs Market:
By Causative Organisms :
Bacterial infections dominate the CRBSI drugs market with 58% share, as gram positive and gram negative bacteria such as Staphylococcus aureus and Enterococcus species are the most common causes of catheter-related bloodstream infections. Fungal infections account for 24% share, driven by rising incidence of Candida related infections among immunocompromised and ICU patients. Viral and parasitic infections collectively hold 18% share, representing a smaller but clinically significant segment, particularly in patients with prolonged catheterization and weakened immune systems.

By Drug Class :
Antibiotics lead the market with 54% share, supported by their frontline use in treating bacterial CRBSIs and the availability of broad spectrum and targeted antimicrobial therapies. Antifungals hold 26% share, driven by increasing fungal bloodstream infections and the growing adoption of echinocandins and azole based therapies. Antivirals represent 12% share, primarily used in specialized clinical scenarios involving viral pathogens. Other drug classes account for the remaining 8% share, including combination therapies and supportive adjunct treatments.

By Route of Administration :
Injectable drugs dominate with 67% share, as intravenous administration ensures rapid onset of action and effective systemic drug delivery in severe bloodstream infections. Oral medications account for 33% share, commonly used for step down therapy once patients are stabilized or for managing mild to moderate infections in outpatient settings.

By Distribution Channel :
Hospital pharmacies lead the market with 52% share, driven by the high prevalence of CRBSI treatment within inpatient settings, especially intensive care units and oncology wards. Retail pharmacies hold 28% share, supported by discharge prescriptions and outpatient antimicrobial therapy. Online pharmacies account for 20% share, benefiting from increasing digital healthcare adoption, home delivery services, and improved access to long term antimicrobial treatments.

☛ Regional Analysis :
North America - 45%
North America leads with 45% share, driven by high catheter usage, advanced healthcare, and key approvals like DefenCath in the U.S.

Europe - 25%
Europe accounts for 25% share, supported by strict infection control regulations and adoption in Germany, UK, and France.

Asia Pacific - 20%
Asia Pacific holds 20% share, fueled by rising hospitalizations and investments in Japan, China, and India.

Latin America - 5%
Latin America represents 5% share, with emerging growth in Brazil and Mexico.

Middle East & Africa - 5%
Middle East & Africa account for 5% share, supported by healthcare infrastructure developments.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=catheter-related-bloodstream-infection-drugs-market?praneetha

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praneetha
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?praneetha

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.